At a glance
- Originator Takeda
- Class Antiplatelets
- Mechanism of Action GPIIb-IIIa antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Thrombosis in Japan (unspecified route)
- 14 Aug 2001 New profile
- 14 Aug 2001 Preclinical development for Thrombosis in Japan (Unknown route)